adenine has been researched along with AIDS, Simian in 85 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance." | 5.35 | Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008) |
| "Although one animal had a gradual increase in viremia from 3 years onwards, the other 4 tenofovir-treated animals maintained undetectable viremia with occasional viral blips (≤ 300 RNA copies/ml plasma)." | 3.78 | Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. ( Abel, K; Canfield, DR; Forthal, DN; Geng, Y; Heneine, W; Jayashankar, K; Johnson, JA; LaBranche, CC; Landucci, G; Lipscomb, J; Montefiori, D; Tarara, RP; Trott, KA; Van Rompay, KK, 2012) |
| "We reported previously on the emergence and clinical implications of simian immunodeficiency virus (SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune responses in suppressing viremia during tenofovir therapy." | 3.74 | Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. ( Bischofberger, N; Blackwood, EJ; Heneine, W; Johnson, JA; Lipscomb, J; Marthas, ML; Matthews, TB; North, TW; Pedersen, NC; Singh, RP; Van Rompay, KK, 2007) |
| " To explore this possibility, we studied whether CD8(+) cells suppress viremia in four rhesus macaques apparently protected by daily or intermittent Truvada (FTC and tenofovir) during 14 low-dose, rectal SHIV(SF162P3) challenges and during a subsequent drug washout period." | 3.74 | Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. ( Adams, DR; Butera, S; Folks, TM; Garcia-Lerma, JG; Heneine, W; Kersh, EN; Luo, W; Mitchell, J; Otten, RA, 2008) |
| "The ability of tenofovir to suppress viremia in simian immunodeficiency virus (SIV)-infected macaques for years despite the presence of virulent viral mutants with reduced in vitro susceptibility is unprecedented in this animal model." | 3.72 | CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. ( Bischofberger, N; Lawson, JR; Marthas, ML; Pahar, B; Singh, RP; Sodora, DL; Van Rompay, KK; Wingfield, C, 2004) |
| " The gel also prevents infection in macaques when applied intravaginally or intrarectally prior to challenge with simian-human immunodeficiency virus (SHIV), but very little pharmacokinetic information for macaques is available to help extrapolate the data to humans and thus inform future development activities." | 1.38 | Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. ( Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N, 2012) |
| " Despite continued gel dosing postinfection, neither breakthrough infection had evidence of drug resistance by ultrasensitive testing of SHIV in plasma and vaginal lavage." | 1.38 | Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. ( Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J, 2012) |
| " We hypothesized that intermittent prophylactic treatment with long-acting antiviral drugs would be as effective as daily dosing in blocking the earliest stages of viral replication and preventing mucosal transmission." | 1.36 | Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. ( Barr, JR; Cong, ME; Folks, TM; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Masciotra, S; Mitchell, J; Otten, R; Pau, CP; Paxton, L; Youngpairoj, AS; Zheng, Q, 2010) |
| " Irrespective of the dosing strategy used, the rsIL-7gly administration transiently increased proliferation of both central memory and naive cells, in both CD4(+) and CD8(+) subsets, without increasing SIV levels in the blood." | 1.36 | Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. ( Assouline, B; Axthelm, MK; Legasse, A; Leone, A; Lifson, JD; Morre, M; Okoye, A; Piatak, M; Picker, LJ; Rohankhedkar, M; Sodora, DL; Villinger, F, 2010) |
| " The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance." | 1.35 | Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008) |
| " Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir." | 1.35 | Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. ( Adams, DR; Cong, ME; Delinsky, D; Folks, TM; García-Lerma, JG; Heneine, W; Jackson, E; Janssen, R; Johnson, JA; Kim, C; Lipscomb, J; Luo, W; Masciotra, S; Monsour, M; Otten, RA; Qari, SH; Schinazi, RF, 2008) |
| "In the treated animal, viremia was controlled to low or undetectable for the study duration, and virus-specific responses remained low." | 1.33 | SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy. ( Carruth, LM; Clements, JE; Li, M; Mankowski, JL; Miller, MD; Queen, LA; Shen, A; Siliciano, RF; Tarwater, PM; Zink, MC, 2005) |
| "Control of off treatment viremia was associated, at least in part, with CD8+ lymphocytes, based on in vivo CD8 depletion studies." | 1.32 | Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. ( Bischofberger, N; Blanchard, J; Cline, AN; Lifson, JD; Pandrea, I; Piatak, M; Purcell, J; Rossio, JL; Veazey, RS, 2003) |
| " Three of four macaques given the same dosing regimen of PMEA had viral load reductions ranging from 1." | 1.31 | Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques. ( Bischofberger, N; Crabbs, C; Greenhouse, J; Jiang, JB; Lewis, MG; Racz, K; Racz, P; Silvera, P; Yalley-Ogunro, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (21.18) | 18.2507 |
| 2000's | 44 (51.76) | 29.6817 |
| 2010's | 23 (27.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, IK | 1 |
| Price, KA | 1 |
| Singletary, T | 1 |
| Srinivasan, P | 2 |
| Smith, JM | 2 |
| Curtis, KA | 2 |
| Perez, S | 1 |
| Johnson, AM | 1 |
| Xiang, SH | 1 |
| Li, J | 1 |
| Foley, BT | 1 |
| Doyle-Meyers, L | 1 |
| Panganiban, A | 1 |
| Kaur, A | 1 |
| Veazey, RS | 2 |
| Wu, Y | 1 |
| Ling, B | 1 |
| Cong, ME | 8 |
| Mitchell, J | 6 |
| Sweeney, E | 1 |
| Bachman, S | 1 |
| Hanson, DL | 5 |
| Heneine, W | 15 |
| García-Lerma, JG | 11 |
| Amancha, PK | 1 |
| Hong, JJ | 1 |
| Rogers, K | 1 |
| Ansari, AA | 2 |
| Villinger, F | 4 |
| Teller, RS | 1 |
| Lo, Y | 1 |
| Dinh, CT | 1 |
| Kiser, PF | 1 |
| Herold, BC | 1 |
| Massud, I | 1 |
| Babusis, D | 2 |
| Deyounks, F | 1 |
| Ray, AS | 4 |
| Rooney, JF | 2 |
| Miller, MD | 4 |
| Van Rompay, KK | 16 |
| Durand-Gasselin, L | 1 |
| Brignolo, LL | 2 |
| Abel, K | 3 |
| Cihlar, T | 1 |
| Spinner, A | 2 |
| Jerome, C | 1 |
| Moore, J | 1 |
| Kearney, BP | 2 |
| Marthas, ML | 15 |
| Reiser, H | 1 |
| Bischofberger, N | 29 |
| Cranage, M | 1 |
| Sharpe, S | 1 |
| Herrera, C | 1 |
| Cope, A | 1 |
| Dennis, M | 1 |
| Berry, N | 1 |
| Ham, C | 1 |
| Heeney, J | 3 |
| Rezk, N | 1 |
| Kashuba, A | 2 |
| Anton, P | 1 |
| McGowan, I | 1 |
| Shattock, R | 1 |
| Kubo, M | 1 |
| Nishimura, Y | 1 |
| Shingai, M | 1 |
| Lee, W | 1 |
| Brenchley, J | 1 |
| Lafont, B | 1 |
| Buckler-White, A | 1 |
| Igarashi, T | 1 |
| Martin, MA | 1 |
| Parikh, UM | 1 |
| Dobard, C | 3 |
| Sharma, S | 3 |
| Jia, H | 1 |
| Martin, A | 4 |
| Pau, CP | 4 |
| Guenthner, P | 1 |
| Smith, J | 3 |
| Kersh, E | 2 |
| Novembre, FJ | 2 |
| Otten, R | 2 |
| Folks, T | 2 |
| Lewis, MG | 5 |
| Norelli, S | 2 |
| Collins, M | 2 |
| Barreca, ML | 2 |
| Iraci, N | 2 |
| Chirullo, B | 2 |
| Yalley-Ogunro, J | 4 |
| Greenhouse, J | 4 |
| Titti, F | 1 |
| Garaci, E | 1 |
| Savarino, A | 2 |
| Youngpairoj, AS | 5 |
| Zheng, Q | 4 |
| Masciotra, S | 2 |
| Kuklenyik, Z | 2 |
| Holder, A | 3 |
| Lipscomb, J | 6 |
| Barr, JR | 1 |
| Paxton, L | 2 |
| Folks, TM | 4 |
| Leone, A | 1 |
| Rohankhedkar, M | 1 |
| Okoye, A | 1 |
| Legasse, A | 1 |
| Axthelm, MK | 1 |
| Piatak, M | 5 |
| Lifson, JD | 10 |
| Assouline, B | 1 |
| Morre, M | 1 |
| Picker, LJ | 1 |
| Sodora, DL | 3 |
| Aung, W | 2 |
| Kuklenyik, S | 1 |
| Luo, W | 4 |
| Lin, CY | 1 |
| Lee, WA | 2 |
| Kennedy, MS | 1 |
| Luckay, A | 1 |
| Hanson, D | 2 |
| Owen, SM | 1 |
| Lugli, E | 1 |
| Mueller, YM | 1 |
| Katsikis, PD | 1 |
| Roederer, M | 1 |
| Nuttall, J | 1 |
| Wang, R | 1 |
| White, N | 1 |
| Allen, P | 1 |
| Roberts, J | 1 |
| Romano, J | 1 |
| Murphey-Corb, M | 3 |
| Rajakumar, P | 1 |
| Michael, H | 1 |
| Nyaundi, J | 1 |
| Didier, PJ | 1 |
| Reeve, AB | 1 |
| Mitsuya, H | 1 |
| Sarafianos, SG | 1 |
| Parniak, MA | 1 |
| Shytaj, IL | 1 |
| Della Corte, A | 1 |
| Acosta, EP | 1 |
| Kersh, EN | 2 |
| Adams, DR | 4 |
| Butler, K | 1 |
| Hendry, RM | 1 |
| McNicholl, JM | 1 |
| Abbott, Z | 1 |
| Geng, Y | 2 |
| Jayashankar, K | 2 |
| Johnson, JA | 5 |
| Trott, KA | 1 |
| LaBranche, CC | 1 |
| Landucci, G | 1 |
| Tarara, RP | 6 |
| Canfield, DR | 6 |
| Forthal, DN | 1 |
| Montefiori, D | 1 |
| Nakasone, T | 1 |
| Murakami, T | 1 |
| Yamamoto, N | 1 |
| Jasny, E | 1 |
| Geer, S | 1 |
| Frank, I | 1 |
| Vagenas, P | 1 |
| Aravantinou, M | 1 |
| Salazar, AM | 1 |
| Gettie, A | 2 |
| Blanchard, JL | 1 |
| Robbiani, M | 1 |
| Schmidt, KA | 3 |
| Lawson, JR | 4 |
| Singh, R | 1 |
| Castillo, AB | 1 |
| Tarantal, AF | 2 |
| Watnik, MR | 1 |
| Martin, RB | 1 |
| Cline, AN | 1 |
| Rossio, JL | 3 |
| Purcell, J | 1 |
| Pandrea, I | 1 |
| Blanchard, J | 1 |
| Cohen, J | 4 |
| Singh, RP | 4 |
| Pahar, B | 2 |
| Wingfield, C | 1 |
| Shen, L | 2 |
| Shen, Y | 2 |
| Huang, D | 1 |
| Qiu, L | 1 |
| Sehgal, P | 2 |
| Du, GZ | 1 |
| Letvin, NL | 2 |
| Chen, ZW | 2 |
| George, MD | 1 |
| Reay, E | 1 |
| Sankaran, S | 2 |
| Dandekar, S | 3 |
| Carruth, LM | 2 |
| Zink, MC | 2 |
| Tarwater, PM | 1 |
| Li, M | 2 |
| Queen, LA | 1 |
| Mankowski, JL | 2 |
| Shen, A | 1 |
| Siliciano, RF | 1 |
| Clements, JE | 2 |
| Gama, L | 1 |
| Bullock, B | 1 |
| Fuller, DH | 2 |
| Rajakumar, PA | 2 |
| Wu, MS | 1 |
| McMahon, CW | 1 |
| Shipley, T | 1 |
| Fuller, JT | 1 |
| Bazmi, A | 1 |
| Trichel, AM | 2 |
| Allen, TM | 1 |
| Mothe, B | 1 |
| Haynes, JR | 1 |
| Watkins, DI | 1 |
| Montefiori, DC | 1 |
| Sexton, JJ | 1 |
| Colón, R | 1 |
| Blackwood, EJ | 2 |
| Taber, R | 1 |
| Dowling, P | 1 |
| Meleason, D | 1 |
| Amedee, A | 1 |
| Grant, RM | 1 |
| Wainberg, MA | 1 |
| Subbarao, S | 2 |
| Otten, RA | 4 |
| Ramos, A | 2 |
| Kim, C | 3 |
| Jackson, E | 2 |
| Monsour, M | 3 |
| Bashirian, S | 1 |
| Johnson, J | 1 |
| Soriano, V | 1 |
| Rendon, A | 1 |
| Hudgens, MG | 1 |
| Butera, S | 3 |
| Janssen, R | 2 |
| Greenberg, AE | 1 |
| Cervasi, B | 1 |
| Paiardini, M | 1 |
| Serafini, S | 1 |
| Fraternale, A | 1 |
| Menotta, M | 1 |
| Engram, J | 1 |
| Lawson, B | 1 |
| Staprans, SI | 1 |
| Piedimonte, G | 1 |
| Perno, CF | 1 |
| Silvestri, G | 1 |
| Magnani, M | 1 |
| Metzner, KJ | 1 |
| Binley, JM | 1 |
| Marx, P | 1 |
| Nixon, DF | 1 |
| Connor, RI | 1 |
| Uberla, K | 2 |
| Rosenwirth, B | 2 |
| Ten Haaft, P | 2 |
| Sutter, G | 1 |
| Erfle, V | 1 |
| Matthews, TB | 1 |
| Pedersen, NC | 7 |
| North, TW | 1 |
| Verhoeven, D | 1 |
| Adams, D | 1 |
| Qari, SH | 1 |
| Delinsky, D | 1 |
| Schinazi, RF | 1 |
| McCarthy, M | 1 |
| Tsai, CC | 5 |
| Follis, KE | 5 |
| Sabo, A | 3 |
| Beck, TW | 3 |
| Grant, RF | 2 |
| Benveniste, RE | 3 |
| Black, R | 1 |
| Grant, R | 1 |
| Bartz, C | 1 |
| Nolte, RE | 1 |
| Cherrington, JM | 4 |
| Berardi, CJ | 3 |
| Mulato, AS | 1 |
| Telm, S | 1 |
| Joag, SV | 1 |
| Li, Z | 2 |
| Foresman, L | 3 |
| Pinson, DM | 1 |
| Stephens, EB | 1 |
| Raghavan, R | 1 |
| Navé, JF | 1 |
| Casara, P | 1 |
| Narayan, O | 3 |
| Nowak, MA | 3 |
| Lloyd, AL | 1 |
| Vasquez, GM | 2 |
| Wiltrout, TA | 1 |
| Wahl, LM | 1 |
| Williams, J | 1 |
| Kinter, A | 1 |
| Fauci, AS | 1 |
| Hirsch, VM | 3 |
| Emau, P | 2 |
| Morton, WR | 2 |
| Agatep, E | 1 |
| Dehqanzada, ZA | 1 |
| Cundy, KC | 1 |
| Aguirre, NL | 4 |
| Lietman, PS | 1 |
| Dailey, PJ | 3 |
| Lamy, PD | 2 |
| Shaw, JP | 1 |
| Cundy, K | 1 |
| Mattapallil, JJ | 1 |
| Smit-McBride, Z | 1 |
| Dailey, P | 1 |
| Bogers, WM | 1 |
| Nieuwenhuis, IG | 1 |
| Niphuis, H | 2 |
| Kuhn, EM | 1 |
| Heeney, JL | 1 |
| Margot, NA | 1 |
| Arnaout, R | 1 |
| Li, L | 2 |
| Parks, TL | 1 |
| Schneider, DK | 1 |
| Kiser, RF | 1 |
| Coalter, VJ | 1 |
| Walsh, G | 1 |
| Imming, RJ | 1 |
| Fisher, B | 2 |
| Flynn, BM | 2 |
| Wodarz, D | 3 |
| Silvera, P | 2 |
| Racz, P | 2 |
| Racz, K | 1 |
| Crabbs, C | 2 |
| Jiang, JB | 1 |
| Wick, D | 1 |
| Self, SG | 1 |
| Smith, MS | 1 |
| Lopez, GJ | 1 |
| Tsay, J | 1 |
| Page, A | 1 |
| Wang, C | 1 |
| Adany, I | 1 |
| Buch, S | 2 |
| Sun, JC | 1 |
| Tran, CA | 1 |
| Lori, F | 1 |
| Xu, J | 1 |
| Varga, G | 1 |
| Zinn, DE | 1 |
| Wagner, W | 1 |
| Tinelli, C | 1 |
| Lisziewicz, J | 1 |
| Kumar, A | 1 |
| Spring, M | 1 |
| Stahl-Hennig, C | 1 |
| Stolte, N | 1 |
| Tenner-Ràcz, K | 1 |
| Lorenzen, D | 1 |
| Hunsmann, G | 1 |
| Dittmer, U | 1 |
| James, JS | 1 |
| McChesney, MB | 1 |
| Zhou, D | 1 |
| Simon, M | 1 |
| Miller, M | 1 |
| Enimi, EA | 1 |
| Henckler, B | 1 |
| Chalifoux, L | 1 |
| Sehgal, N | 1 |
| Gastron, M | 1 |
| Parks, T | 1 |
| Kiser, R | 1 |
| Coalter, V | 1 |
| Czajak, S | 1 |
| Reimann, KA | 1 |
| Schmitz, JE | 1 |
| Ghrayeb, J | 1 |
| Desrosiers, RC | 1 |
| Brice, GT | 1 |
| Mayne, AE | 1 |
| Bostik, P | 1 |
| Mori, K | 1 |
| June, CH | 1 |
| Balzarini, J | 1 |
| Naesens, L | 1 |
| Slachmuylders, J | 1 |
| Rosenberg, I | 1 |
| Holý, A | 1 |
| Schellekens, H | 1 |
| De Clercq, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation[NCT01136759] | Phase 1 | 232 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| HIV Pre-Exposure Prophylaxis Priming of Immune Effectors[NCT02593409] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-05-25 | Recruiting | ||
| The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection[NCT03205566] | Phase 4 | 38 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)[NCT01214759] | Phase 4 | 103 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician. (NCT03205566)
Timeframe: Through Study completion, an average of 55 days
| Intervention | Adverse event (Number) |
|---|---|
| Arm A Raltegravir | 12 |
| Arm B Raltegravir Lamivudine | 15 |
"The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .~High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL" (NCT03205566)
Timeframe: Through Study completion, an average of 55 days
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Plasma: High Dose Challenge in rectal tissue | Plasma: Low viral dose challenge in rectal tissue | Rectal: high viral dose challenge in rectal tissue | Rectal: Low viral dose challenge in rectal tissue | Plasma: high viral dose challenge in vaginal tissu | Plasma: low viral dose challenge in vaginal tissue | Plasma: high dose in vaginal tissue | Plasma: low dose in vaginal tissue | |
| Lamivudine During Combination Treatment | 265.10 | 265.10 | 1722.02 | 1722.02 | 266.40 | 169.10 | 1557.80 | 1437.80 |
| Raltegravir | NA | 979.8 | NA | 729.36 | NA | 979.8 | NA | 607.60 |
| Raltegravir During Combination Treatment | 669.90 | 669.90 | 862.35 | 862.35 | 828.60 | 281.60 | 648.24 | 273.02 |
Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time from first dose of drug to maximum rectal ex vivo protection from high titer HIV infection | Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infection | Time from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection | ||
| Raltegravir | 3 | 2 | 2.67 | 3 |
Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infection | Time from first dose of drug to maximum rectal ex vivo protection from High titer HIV infection | Time from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection | ||
| Raltegravir Lamivudine | 2 | 2 | 3 | 3.67 |
Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed. (NCT03205566)
Timeframe: 5 days post last dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time to cessation of rectal ex vivo protection from high HIV dose challenge post ART at steady state | Time to cessation of rectal ex vivo protection from low HIV dose challenge post ART at steady state | Time to cessation of vaginal ex vivo protection from high HIVdose challenge post ART at steady state | Time to cessation of vaginal ex vivo protection from low HIV dose challenge post ART at steady state | |
| Raltegravir | 3.33 | NA | 4 | 5 |
| Raltegravir Lamivudine | NA | NA | NA | NA |
This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV. (NCT01214759)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Truvada and Raltegravir | 0 |
(NCT01214759)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Truvada and Raltegravir | 85 |
85 other studies available for adenine and AIDS, Simian
| Article | Year |
|---|---|
A multiplex assay for detection of SHIV plasma and mucosal IgG and IgA.
Topics: Adenine; Adenoviruses, Simian; Administration, Intravaginal; Animals; Anti-HIV Agents; Biomarkers; D | 2017 |
Persistence of SIV in the brain of SIV-infected Chinese rhesus macaques with or without antiretroviral therapy.
Topics: Adenine; Amino Acid Sequence; Animals; Antiretroviral Therapy, Highly Active; Basal Ganglia; Brain S | 2018 |
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Deoxycytidine; Disease Transmission, Infect | 2013 |
In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antibodies, Monoclonal; Apoptosis; CD4-Positive T-Lymphocy | 2013 |
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.
Topics: Adenine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Female; HIV Infections; Macaca nemes | 2015 |
Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Emtricitabine; Macaca; Simian Acquired | 2016 |
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV- | 2008 |
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells; | 2008 |
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells; | 2008 |
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells; | 2008 |
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells; | 2008 |
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; | 2009 |
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combin | 2009 |
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun | 2010 |
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
Topics: Adenine; Administration, Oral; Animals; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir D | 2010 |
Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses.
Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Po | 2010 |
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; L | 2010 |
Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Viral; Em | 2011 |
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Deoxyadenine Nucleotides; HIV Infections; HIV Re | 2011 |
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Deoxy | 2011 |
IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.
Topics: Adaptive Immunity; Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; | 2011 |
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Antiviral Agents; Area Under | 2012 |
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Drug Stability; Female; Half-Life; HIV Infection | 2012 |
Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Deoxyadenosines; Deoxycytidine; Emtricitabine; | 2012 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; D | 2012 |
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytoki | 2012 |
Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Drug Administration Schedule; Injections, | 2012 |
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Topics: Adenine; Alleles; Animals; Antibodies, Viral; Antibody Formation; Antiviral Agents; CD4 Lymphocyte C | 2012 |
Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Coun | 2012 |
Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtr | 2012 |
Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
Topics: Adenine; Administration, Topical; Animals; Anti-HIV Agents; Disease Models, Animal; Macaca; Organoph | 2002 |
Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).
Topics: Adenine; Animals; Bone Remodeling; Calcification, Physiologic; Macaca mulatta; Organophosphonates; O | 2002 |
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Topics: Adenine; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA Primers; Gene Products, env; Gene | 2003 |
Cambodia: can a drug provide some protection?
Topics: Adenine; Animals; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; Haplorhini | 2003 |
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Topics: Adenine; Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Macaca mulatta; Organophosphonates; | 2004 |
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; CD4-Positive T-Lymphocytes; | 2004 |
Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
Topics: Adenine; Amino Acid Sequence; Animals; Cattle; CD4-Positive T-Lymphocytes; Disease Models, Animal; D | 2004 |
Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antibody Formation; Antigen Presentation; CD4-Positive T-L | 2005 |
SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Immunity, Cellul | 2005 |
The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; D | 2005 |
DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cell Proliferat | 2006 |
Retrovirus meeting. Novel attacks on HIV move closer to reality.
Topics: Adenine; Animals; Anti-HIV Agents; Evolution, Molecular; HIV Infections; HIV-1; Humans; Organic Chem | 2006 |
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Biomarkers; Drug Resistance, Viral; Immune Tole | 2006 |
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
Topics: Adenine; Administration, Oral; Administration, Topical; Alanine; Animals; Anti-HIV Agents; Genetic P | 2006 |
Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate.
Topics: Adenine; Amino Acid Sequence; Animals; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecula | 2006 |
Chemoprophylaxis of HIV infection: moving forward with caution.
Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1; | 2006 |
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral; | 2006 |
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Car | 2006 |
Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; CD8-Positive T-Lymphocytes; Chronic Disease; D | 2006 |
Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antibodies, Viral; Fusion Proteins, gag-pol; Genetic Vecto | 2007 |
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Topics: Adenine; Amino Acid Substitution; Animals; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Disease Mode | 2007 |
Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Di | 2007 |
Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antibodies, Viral; Chemoprevention; Disea | 2007 |
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
Topics: Adenine; Animals; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Macaca; Macaca mulatta | 2008 |
Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies; Antibody Specificity; Antiviral Agents; CD8-Positive | 2008 |
Drug prevents SIV infection.
Topics: Adenine; Animals; Antiviral Agents; Macaca fascicularis; Organophosphonates; Organophosphorus Compou | 1995 |
AIDS research. New drug shows promise in monkeys.
Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Ve | 1995 |
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Base Sequence; Cells, Cultured; HIV Infection | 1995 |
Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques.
Topics: Adenine; Animals; Antiviral Agents; Chronic Disease; DNA, Viral; Leukocytes, Mononuclear; Lymphocyte | 1995 |
Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques.
Topics: Adenine; Animals; Antibodies, Viral; Base Sequence; DNA Primers; DNA, Viral; Dose-Response Relations | 1994 |
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Drug Resistance; Immunoglobu | 1996 |
Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques.
Topics: Adenine; Animals; Antiviral Agents; Macaca mulatta; Organophosphonates; Simian Acquired Immunodefici | 1997 |
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.
Topics: Adenine; AIDS Vaccines; Animals; Antiviral Agents; Cells, Cultured; Humans; Kinetics; Lymphocytes; M | 1997 |
Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Topics: Adenine; Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Adm | 1998 |
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; D | 1998 |
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Dose-Response Relationship, | 1998 |
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Humans; Injections, Subcutaneous; Macaca mulatt | 1999 |
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Biological Transport; Body Weight; Female; Imm | 1999 |
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Macaca; Mutation; Organophosphonates; Organoph | 1999 |
Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2.
Topics: Adenine; Animals; Antiviral Agents; CD11 Antigens; CD4-Positive T-Lymphocytes; Cell Division; Immuno | 1999 |
Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; HIV Envelope Protein gp120; HIV Reverse Transcri | 2000 |
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Topics: Adenine; Administration, Oral; Animals; Animals, Newborn; Antiviral Agents; Macaca mulatta; Organoph | 2000 |
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
Topics: Adenine; Animals; Antiviral Agents; Female; Macaca mulatta; Organophosphonates; Organophosphorus Com | 2000 |
Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Antiviral Agents; Lymph Nodes; Macaca mulatta; | 2000 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Hu | 2000 |
Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Cerebrospinal Fluid; Disease Models, Animal | 2000 |
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Tra | 2000 |
Control of SIV rebound through structured treatment interruptions during early infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8- | 2000 |
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV In | 2001 |
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.
Topics: Adenine; Animals; Anti-HIV Agents; Apoptosis; CD8-Positive T-Lymphocytes; Disease Models, Animal; Hu | 2001 |
PMPA beats SIV again.
Topics: Adenine; Anemia; Animals; Antiviral Agents; Hemoglobins; Macaca; Organophosphonates; Phosphates; Sim | 1996 |
PMPA--first human results.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Haplorhini; HIV; HIV Infections; Human | 1997 |
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; DNA, Viral; Humans; Lymphocyte Activation; Mac | 2001 |
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; HIV Protease Inhibitors; Indinavir; Macaca mula | 2001 |
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
Topics: Adenine; Animals; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Female; Macaca mulatta; Organophospho | 2001 |
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Blood Transfusion, Autologous; CD4-Positive T | 2002 |
Vaccines. Monkey puzzles.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS Vaccines; Animals; Anti-HIV Agents; Clinical Trial | 2002 |
9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Blotting, Western; Cell Line; HIV Envelope Pr | 1991 |